文献速递毛发、甲与色素性疾病

斑秃研究者整体评估量表:临床试验中评估临床有意义成功的工具

The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
PubMed 文献 · Br J Dermatol · 2020-04-03

本研究通过在美国对10名专家皮肤科医生和30名斑秃患者(≥50%头皮脱发)进行定性访谈,开发了斑秃研究者整体评估量表(AA-IGA™)。该量表为五级有序静态测量,评估头皮脱发严重程度。多数医生和患者认为,对于≥50%头皮脱发的患者,治疗成功定义为头发再生至≤20%头皮脱发。建议使用脱发严重程度工具(SALT)评估脱发范围,AA-IGA可提供临床有意义的治疗成功判定。

要点

  • AA-IGA™为五级有序量表,评估斑秃头皮脱发严重程度。
  • 患者和医生认为治疗成功为达到≤20%头皮脱发。
  • 推荐SALT评估脱发范围,AA-IGA判定临床有意义的成功。

核心结论

  • AA-IGA™是一种稳健的有序测量工具,提供反映患者和专家观点的临床有意义脱发分级。
  • 对于≥50%头皮脱发的斑秃患者,治疗成功定义为头发再生至≤20%头皮脱发。

研究设计与样本

  • 在美国进行定性访谈,包括专家皮肤科医生和≥50%头皮脱发的斑秃患者。
  • 专家临床医生10名,成人患者25名,青少年患者5名。

主要发现

  • 专家临床医生判断斑秃治疗成功的中位头皮毛发量为80%。
  • 患者感知的治疗成功(未达100%头皮毛发)为中位80%头皮毛发(约70-90%)。
  • 几乎所有的临床医生和患者同意,对于≥50%头皮脱发的患者,成功治疗为头发再生至≤20%头皮脱发。

关键数值与推荐

  • AA-IGA™包含五个严重程度类别,为有序静态测量。
  • 推荐使用脱发严重程度工具(SALT)评估头皮脱发范围(0-100%)。

临床怎么用

  • AA-IGA可用于临床试验中评估斑秃治疗反应,定义临床有意义的成功为≤20%头皮脱发。
  • 临床评估斑秃治疗结果时可结合SALT和AA-IGA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Content-valid and clinically meaningful instruments are required to evaluate outcomes of therapeutic interventions in alopecia areata (AA). OBJECTIVES: To develop an Investigator's Global Assessment (IGA) to interpret treatment response in AA treatment studies. METHODS: Qualitative interviews were conducted in the USA with expert dermatologists and with patients with AA who had experienced ≥ 50% scalp-hair loss. Thematic data analysis identified critical outcomes and evaluated the content validity of the new IGA. RESULTS: Expert clinicians (n = 10) judged AA treatment success by the amount of scalp-hair growth (median 80% scalp hair). Adult (n = 25) and adolescent (n = 5) patients participated. Scalp-hair loss was the most bothersome AA sign/symptom for most patients. Perceived treatment success - short of 100% scalp hair - was the presence of ~ 70-90% scalp hair (median 80%). Using additional clinician and patient insights, the Alopecia Areata Investigator Global Assessment (AA-IGA™) was developed. This clinician-reported outcome assessment is an ordinal, static measure comprising five severity categories of scalp-hair loss. Nearly all clinicians and patients in this study agreed that, for patients with ≥ 50% scalp-hair loss, successful treatment would be hair regrowth resulting in ≤ 20% scalp-hair loss. CONCLUSIONS: We recommend using the Severity of Alopecia Tool to assess the extent (0-100%) of scalp-hair loss. The AA-IGA is a robust ordinal measure providing distinct and clinically meaningful gradations of scalp-hair loss that reflects patients' and expert clinicians' perspectives and treatment expectations. What is already known about this topic? The Severity of Alopecia Tool is widely used to assess the extent of scalp-hair loss in patients with alopecia areata. Guidelines define treatment success as a 50% improvement in scalp hair, and clinical trials have used dynamic thresholds of 50% and 90%. However, there is no clinical consensus on these endpoints, and patient perspectives on treatment success are unknown. What does this study add? Through qualitative interviews with 10 expert dermatologists and 30 patients with alopecia areata who had experienced ≥ 50% scalp-hair loss, we developed the Alopecia Areata Investigator Global Assessment (AA-IGA™) to measure five clinically meaningful gradations of alopecia areata scalp-hair loss that reflects patients' and clinicians' perspectives and expectations of treatment success in alopecia areata treatment studies. What are the clinical implications of this work? The AA-IGA is a robust ordinal measure that can inform clinical evaluation of alopecia areata treatment outcomes. The AA-IGA can be used to determine clinically meaningful treatment success for alopecia areata, with success defined by patients and clinicians as reaching ≤ 20% scalp-hair loss. Linked Comment: Blome. Br J Dermatol 2020; 183:609.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wyrwich KW, Kitchen H, Knight S, et al. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. Br J Dermatol. 2020. PMID: 31970750. doi:10.1111/bjd.18883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。